FN1 and neoplasm: The fibrin–fibronectin complexes, uniquely overexpressed on the walls of tumor vessels and in tumor stroma, can specifically recognize CREKA peptide, which implemented thrombin‐controlled release at the tumor tissues form the nanotheranostic agents.